Disclosures for "DOC1021 Cell-based Immunotherapy in Combination With Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results From an Expanded Access Protocol of a Phase I Trial"
-
The institution of Dr. Zhu has received research support from Novocure, Inc. The institution of Dr. Zhu has received research support from Five Prime pharmaceutical. The institution of Dr. Zhu has received research support from Denovo, inc. The institution of Dr. Zhu has received research support from Boston Biomedical Sumitomo Dainippon Pharma Global Oncology. The institution of Dr. Zhu has received research support from CNS pharmaceutical. The institution of Dr. Zhu has received research support from ABM Therapeutics Corporation . The institution of Dr. Zhu has received research support from Chimerix Inc.
-
Dr. Esquenazi has nothing to disclose.
-
Author has nothing to disclose
-
Miss Vu has nothing to disclose.
-
Dr. Zvavanjanja has nothing to disclose.
-
Mr. Trivedi has nothing to disclose.
-
Ms. Liu has nothing to disclose.
-
Mrs. Namekar has nothing to disclose.
-
Mr. Ernste has received intellectual property interests from a discovery or technology relating to health care.
-
Nitin Tandon has stock in BrainDynamics. The institution of Nitin Tandon has received research support from NIH.
-
Ms. Schumann has received personal compensation for serving as an employee of Diakonos Oncology.
-
Ms. Duus has received personal compensation for serving as an employee of Diakonos Oncology.
-
Dr. Aguilar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Diakonos Oncology. An immediate family member of Dr. Aguilar has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Candel Therapeutics. Dr. Aguilar has stock in Candel Therapeutics .
-
Dr. Georges has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. konduri has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Diakonos Oncology. Dr. konduri has stock in Diakonos Oncology. The institution of Dr. konduri has received research support from Diakonos Oncology.
-
Dr. Decker has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Diakonos Oncology Corp.. Dr. Decker has stock in Diakonos Research, Ltd.. The institution of Dr. Decker has received research support from NIH. The institution of Dr. Decker has received research support from ALSF. The institution of Dr. Decker has received research support from Cancer Cures 4 Kids. Dr. Decker has received intellectual property interests from a discovery or technology relating to health care.